Eli Lilly and Co (NYSE:LLY) had declared a cash dividend of $0.5100 on Jun 20, 2016. The shares will quote ex-dividend on Aug 11, 2016 and the record date has been fixed for Aug 15, 2016. On Jun 20, 2016 share price, the yield comes out to be 2.7620%. The dividend payable date has been fixed on Sep 9, 2016.
In a different note, On May 2, 2016, Leerink Swann said it Maintains its rating on Eli Lilly and Co. In the research note, the firm Raises the price-target to $96.00 per share. The shares have been rated ‘Outperform’ by the firm. Societe Generale said it Initiates Coverage on Eli Lilly and Co, according to a research note issued on Apr 6, 2016. The shares have been rated ‘Hold’ by the firm.
Eli Lilly and Co (LLY) made into the market gainers list on Fridays trading session with the shares advancing 0.53% or 0.39 points. Due to strong positive momentum, the stock ended at $74.33, which is also near the day’s high of $75.12. The stock began the session at $72.45 and the volume stood at 1,04,71,256 shares. The 52-week high of the shares is $92.85 and the 52 week low is $67.88. The company has a current market capitalization of $82,048 M and it has 1,10,38,37,000 shares in outstanding.
Eli Lilly and Co(LLY) last announced its earnings results on Apr 26, 2016 for Fiscal Year 2016 and Q1.Company reported revenue of $4.87B. Analysts had an estimated revenue of $4.82B. Earnings per share were $0.83. Analysts had estimated an EPS of $0.85.
Several Insider Transactions has been reported to the SEC. On Jun 13, 2016, Melissa S Barnes (Chief Eth/Cmpl Ofcr & SVP, ERM) sold 992 shares at $73.77 per share price.Also, On Jun 1, 2016, Endowment Inc Lilly (10% owner) sold 200,000 shares at $75.12 per share price.On May 16, 2016, Jackson P Tai (director) purchased 1,080 shares at $75.75 per share price, according to the Form-4 filing with the securities and exchange commission.
Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers develops manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division which develops manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States Puerto Rico and 11 other countries. Its products include endocrinology products neuroscience products oncology products cardiovascular products products for food animals products for companion animals and Novartis AH products.